<DOC>
	<DOCNO>NCT00760669</DOCNO>
	<brief_summary>The purpose observational study evaluate safety effectiveness infliximab injection actual condition use participant , learn adverse event .</brief_summary>
	<brief_title>An Observational Study Infliximab Injection Ankylosing Spondylitis , Rheumatoid Arthritis , Psoriatic Arthritis Psoriasis Participants</brief_title>
	<detailed_description>This observational , prospective ( study follow participant forward time ) study assess safety efficacy infliximab injection post-marketing use identify problem related adverse event participant ankylose spondylitis ( chronic inflammatory condition affect axial joint ) , rheumatoid arthritis ( chronic systemic disease , primarily joint , mark inflammatory change synovial membrane articular structure ) , psoriasis ( scaly skin rash ) psoriatic arthritis ( type inflammatory arthritis associate psoriasis ) . Participants rheumatoid arthritis receive 6 dos infliximab 3 milligram per kilogram ( mg/kg ) intravenous infusion ( fluid medicine deliver vein way needle ) Week 0 , 2 , 6 observe 30 week ; ankylose spondylitis , psoriasis psoriatic arthritis also receive 6 dos injection observe 24 30 week . Efficacy evaluate Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) , Erythrocyte Sedimentation Rate ( ESR ) , C-reactive protein ( CRP ) , Psoriasis Area Severity Index ( PASI ) , swollen joint count tender joint count . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Participants ankylose spondylitis show adequate response general treatment increase serological index relate severe axial symptom inflammation Participants rheumatoid arthritis show insufficient response disease modify antirheumatic drug ( DMARD ) include methotrexate Participants serious , active progressive disease previously treat methotrexate DMARD Participant moderate serious plaque psoriasis unresponsive , contra indicant intolerable systemic therapy include cyclosporine , methotrexate Psoralen UltraViolet A ( PUVA ) Participant active , progressive , psoriatic arthritis show insufficient response DMARD treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Spondylitis , Ankylosing</keyword>
	<keyword>Arthritis , Rheumatoid</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Arthritis , Psoriatic</keyword>
	<keyword>Infliximab</keyword>
	<keyword>Remicade</keyword>
</DOC>